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Abstract 
Background: Type III polyketide synthases (PKSs) contribute to the synthesis of many economically important 
natural products, which are typically produced by direct extraction from plants or synthesized chemically. For exam-
ple, humulone and lupulone (Fig. 1a) in hops (Humulus lupulus) account for the characteristic bitter taste of beer and 
display multiple pharmacological effects. 4-Hydroxy-6-methyl-2-pyrone is a precursor of parasorboside contributing 
to insect and disease resistance of plant Gerbera hybrida, and was recently demonstrated to be a potential platform 
chemical.
Results: In this study, we achieved simultaneous biosynthesis of phlorisovalerophenone, a key intermediate of 
humulone biosynthesis and 4-hydroxy-6-isobutyl-2-pyrone in Escherichia coli from glucose. First, we constructed a 
biosynthetic pathway of isovaleryl-CoA via hydroxy-3-methylglutaryl CoA followed by dehydration, decarboxylation 
and reduction in E. coli. Subsequently, the type III PKSs valerophenone synthase or chalcone synthase from plants 
were introduced into the above E. coli strain, to produce phlorisovalerophenone and 4-hydroxy-6-isobutyl-2-pyrone at 
the highest titers of 6.4 or 66.5 mg/L, respectively.
Conclusions: The report of biosynthesis of phlorisovalerophenone and 4-hydroxy-6-isobutyl-2-pyrone in E. coli adds 
a new example to the list of valuable compounds synthesized in E. coli from renewable carbon resources by type III 
PKSs.
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Escherichia coli
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Background
A large number of natural products are synthesized by 
type III polyketide synthases (PKSs). These compounds 
play an important role in human nutrition and health, 
and have recently expanded their roles as platform chem-
icals. Acylphloroglucinol derivatives have been isolated 
from a number of plants [1–3]. Their chemical struc-
tures and intriguing biological activities have attracted 
increasing attention in recent years. Humulone and lupu-
lone (Fig. 1a) in hops (Humulus lupulus) account for the 
characteristic bitter taste of beer and display multiple 
pharmacological effects [4]. Hyperforin (Fig.  1a) is one 
of the main active constituents in extracts of Hypericum 
perforatum used for the treatment of depression [5]. The 
4-hydroxy-2-pyrone analogues display multiple biological 
activities and are valuable pharmaceutical precursors [6]. 
4-Hydroxy-6-methyl-2-pyrone, also known as triacetic 
acid lactone (TAL, Fig.  1b) is a precursor of gerberin 
and parasorboside, which could protect Gerbera hybrid 
from fungal pathogens and attack by insects [7]. Fistupy-
rone (4-hydroxy-6-isovaleryl-2-pyrone) (Fig.  1b) was 
isolated from Streptomyces sp. TP-A0569 and showed 
inhibition of the infection of Chinese cabbage by a fun-
gus Alternaria brassicicola [8]. Germicidin homologs 
(Fig.  1b) arisen from streptomyces inhibit spore ger-
mination and Na+/K+ ATPase [9, 10]. More recently, 
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4-hydroxy-2-pyrones were reported to be potential plat-
form chemicals (Additional file 1: Figure S1a) [11–13].
Advances in synthetic biology and metabolic engineer-
ing greatly promoted biosynthesis of a variety of valuable 
compounds, for instance, flavonoids produced by type III 
PKSs [14, 15] in microbial hosts. Biological production 
of phloroglucinol (Fig.  1a) and TAL (Fig.  1b) from glu-
cose has also been accomplished using genetically modi-
fied microorganisms [6, 16–19]. However, biosynthesis 
of acylphloroglucinols and TAL analogues from renew-
able feedstocks in Escherichia coli has not been well 
investigated.
The acylphloroglucinol cores, phlorisovalerophenone 
(PIVP) and phlorisobutyrophenone (PIBP) are formed by 
condensation of three malonyl-CoA-derived acetate units 
with isovaleryl-CoA or isobutyryl-CoA as the starter 
units [4, 20]. The enzyme valerophenone synthase (VPS) 
involved in the formation of PIVP in the biosynthesis 
of humulone has been characterized [21–23]. VPS is a 
homologue of chalcone synthase (CHS). They share the 
same reaction mechanism namely claisen condensation, 
but differ in substrate specificity. CHS catalyzes conden-
sation of one molecule of p-coumaroyl-CoA and three 
molecules of malonyl-CoA to form naringenin-chalcone. 
Fig. 1 Examples of phloroglucinols (a) and 2-pyrones (b) synthesized by type III PKS. PIBP phlorisobutyrophenone; PIVP phlorisovalerophenone; TAL 
4-hydroxy-6-methyl-2-pyrone (triacetic acid lactone); HIPP 4-hydroxy-6-isopropyl-2-pyrone; HIBP 4-hydroxy-6-isobutyl-2-pyrone
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However, VPS preferentially uses isovaleryl-CoA or 
isobutyryl-CoA instead of p-coumaroyl-CoA as the 
starter unit to condense with three molecules of malo-
nyl-CoA to form PIVP [21, 23]. Recently, dual functional 
CHS/VPS have also been reported. A CHS, FvCHS2-1 
from strawberry (Fragaria vesca) was identified to be 
responsible for acylphloroglucinols synthesis in straw-
berry fruit [3]. Intriguingly, in vitro experiments demon-
strated that type III PKSs such as VPS and CHS usually 
also synthesize TAL analogues, 4-hydroxy-6-isobutyl-
2-pyrone (HIBP) and 4-hydroxy-6-isopropyl-2-pyrone 
(HIPP) (Fig.  1b), carrying isobutyl or isopropyl at posi-
tion 6 with isovaleryl-CoA or isobutyl-CoA as the starter 
unit and malonyl-CoA as the extender unit.
In this work, we engineered the synthesis of isovaleryl-
CoA in E. coli by recruiting a biosynthetic pathway via 
hydroxy-3-methylglutaryl CoA (HMG-CoA), an inter-
mediate of the mevalonate pathway (Fig.  2a) [24]. The 
VPS from hops (Humulus lupulus) HlVPS, the CHS 
from strawberry (Fragaria vesca) FvCHS2-1 and a newly 
cloned CHS from H. perforatum HpCHS were intro-
duced into the isovaleryl-CoA producing E. coli strain 
separately, led to the simultaneous production of PIVP 
and HIBP at different ratios. The highest titers of PIVP 
and HIBP produced by the recombinant strains reached 
6.4 and 66.5  mg/L, respectively. This work adds new 
products to the list of valuable compounds biosynthe-
sized in E. coli using type III PKSs and lays a foundation 
for microbial synthesis of not only acylphloroglucinol 
derivatives, but also potential platform chemicals.
Methods
Strains, plasmids and medium
Strains and plasmids used in this study are listed in 
Table  1. Luria–Bertani (LB) medium was used for the 
propagation of E. coli cells for plasmid construction. Ter-
rific Broth (TB) medium (12  g/L tryptone, 24  g/L yeast 
extract, 4  mL/L glycerol, 2.3  g/L KH2PO4, and 12.5  g/L 
K2HPO4) and modified M9 medium (1  ×  M9 minimal 
salts, 20 g/L glucose, 10 g/L yeast extract, 2 mM MgSO4, 
and 0.1 mM CaCl2) were used for protein expression and 
PIVP production, respectively. Ampicillin (100  mg/L) 
and streptomycin (100 mg/L) were added to the medium 
as needed.
Construction of plasmids
Oligonucleotide primers used in this study are sum-
marized in Additional file  1: Table S1. AibA, aibB, aibC 
and liuC were PCR-amplified from Myxococcus xanthus 
(CGMCC 1.3865) genome with primer pairs aibA-F/
aibA-R, aibB-F/aibB-R, aibC-F/aibC-R or liuC-F/liuC-R, 
respectively. The amplified gene products of aibA, aibB 
and aibC were digested with restriction enzyme and 
simultaneously subcloned into the multiple cloning 
sites (MCS) 1 of pETDuet-1 by Golden Gate [25] clon-
ing using AarI. Subsequently, the gene product of liuC 
was digested and ligated into the above resulting plas-
mid using HindIII/AflII to yield the final plasmid pET-
A. Here, the sequences of T7 promoter, lac operator 
and ribosome binding site (RBS) from pETDuet-1 were 
incorporated into the primer design, so each gene was 
driven by a single T7 promoter. ERG10 and ERG13 were 
PCR-amplified from Saccharomyces cerevisiae BY4742 
genome with primer pairs ERG10-F/ERG10-R or ERG13-
F/ERG13-R, respectively. First, the ERG13 fragment was 
digested and cloned into NcoI/BamHI sites of pCDF-
Duet-1. The ERG10 fragment was digested and ligated 
into the above plasmid via NdeI/XhoI sites, generating 
the recombinant plasmid pCDF-E. The HlVPS gene from 
hops (GenBank: AB015430.1) was codon optimized for 
expression in E. coli and synthesized by Shanghai Gen-
eray Biotech Co., Ltd. (Shanghai, China), designated 
as HlVPSsyn (Additional file  1: Table S2). HlVPSsyn was 
PCR-amplified with primer pair VPS-F/VPS-R, and 
cloned into pET28a through NdeI/AflII sites generat-
ing the intermediate expression vector pET28a-HlVPS. 
The T7-HlVPSsyn fragment with a T7 promoter and an 
N-terminal His tag was PCR-amplified from pET28a-
HlVPS with primer pair T7VPS-F/T7VPS-R, digested 
and ligated into pCDF-E via NotI/AflII to generate the 
final recombinant plasmid pCDF-EV1. FvCHS2-1 from 
strawberry (GenBank: XM_004306495.1) was codon 
optimized for expression in E. coli and synthesized by 
Shanghai Generay Biotech Co., Ltd. (Shanghai, China), 
designated as FvCHS2-1syn (Additional file  1: Table S2). 
HpCHS was obtained from the mRNA of H. perforatum 
by RT-PCR. RNA of H. perforatum callus was isolated by 
RNAprep pure Plant Kit from Tiangen Biotech Co., Ltd. 
(Beijing, China). Reverse transcription was performed 
using the First Strand cDNA Synthesis Kit from Toyobo 
Co., Ltd. (Osaka, Japan). PCR reactions were performed 
using High Fidelity PCR system (Fermentas, Germany) 
with primer pair HpCHS-F/HpCHS-R. The HpCHS 
sequence was submitted into NCBI database (GenBank: 
KU180217). FvCHS2-1syn and HpCHS were ligated into 
pCDF-E individually using the same method as pCDF-
EV1 construction, yielding pCDF-EV2 and pCDF-EV3, 
respectively.
Biosynthesis of isovaleryl‑CoA in E. coli
The plasmids, pET-A and pCDF-E, were electropo-
rated into BL21 (DE3), generating the recombinant 
strain APG-IV. The strain APG-0 harboring pETDuet-1 
and pCDFDuet-1 was used as the control. A 1  mL ali-
quot of the overnight cultured single colony was inocu-
lated into 50 mL LB medium containing antibiotics and 
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cultivated at 37  °C, 200 rpm with shaking. When OD600 
of the culture reached 0.6, 0.1  mM isopropyl-β-D-
thiogalactoside (IPTG) was added to induce recombinant 
protein expression at 30  °C for 12  h. Subsequently, the 
cells were centrifuged (4000 rpm, 30 °C, 10 min), washed 
and resuspended in 50  mL modified M9 medium and 
Fig. 2 The biosynthetic pathway of phlorisovalerophenone (PIVP) and 4-hydroxy-6-isobutyl-2-pyrone (HIBP) constructed from glucose in E. coli. 
a The biosynthetic pathway of isovaleryl-CoA. Red arrows represent the constructed isovaleryl-CoA biosynthetic pathway via HMG-CoA followed 
by dehydration, decarboxylation and reduction. Black arrows represent the biosynthesis of isovaleryl-CoA catalyzed by the BCDH complex. Dotted 
arrows represent the mevalonate-dependent pathway of isoprenoid. b The formation of PIVP and HIBP catalyzed by VPS. PDH pyruvate dehydro-
genase complex, ACC acetyl-CoA carboxylase, ERG10 acetyl-CoA acetyltransferase, ERG13 HMG-CoA synthase, LiuC HMG-CoA dehydratase, AibA/B 
MG-CoA decarboxylase, AibC DMA-CoA reductase, Als acetolactate synthase, IlvC ketol-acid reductoisomerase, IlvD dihydroxy-acid dehydratase, LeuA 
α-isopropylmalate synthase, LeuCD α-isopropylmalate isomerase complex, LeuB isopropylmalate dehydrogenase, BCDH branched-chain α-keto acid 
dehydrogenase complex, BCAT branched-chain amino acid transaminase, VPS valerophenone synthase
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cultured at 30 °C for 3 h. The cell culture was chilled on 
ice for 10  min. Cells were harvested by centrifugation 
(4000  rpm, 4  °C, 10  min) and resuspended in 1.5  mL 
extraction buffer (methanol:acetonitrile:water  =  2:2:1, 
v/v, with 0.1 % formic acid). After sonication and centrif-
ugation, 50 μL of the supernatants were used for HPLC 
and LC–MS analysis.
Biosynthesis of PIVP and HIBP in E. coli
Escherichia coli strain BL21 (DE3) was transformed with 
plasmids pET-A and pCDF-EV1, pET-A and pCDF-EV2 
or pET-A and pCDF-EV3 to generate the recombinant 
strains APG-1, APG-2 or APG-3, respectively. Two stage 
fermentation processes were applied to achieve the pro-
duction of PIVP and HIBP. The first stage is for pathway 
genes overexpression, and recombinant strains were cul-
tivated in TB medium. Single colonies were cultured in 
3 mL LB medium with antibiotics at 37 °C for 7 h as seed 
culture, 1  mL of which was transferred into 50  mL  TB 
medium with antibiotics and cultured in a shake flask 
at 37  °C until an OD600 of 1.2 followed by addition of 
0.1  mM IPTG. To determine optimal temperature for 
fermentation conditions at the stage, the culture was 
incubated at 16, 23 or 30 °C for 16 h. Different concen-
trations of IPTG (0.01, 0.05, 0.1, 0.2 or 0.3  mM) were 
also added in the TB medium to determine the opti-
mal concentrations. The cell pellets were harvested by 
centrifugation and resuspended in an equal volume of 
modified M9 medium and fermented at 30 °C, 200 rpm 
for secondary metabolite production as the second 
stage. Time course for production of PIVP and HIBP 
by strain APG-1 was determined for 12, 24, 36, 48 and 
60 h. Subsequently, the culture broth was centrifuged at 
4000  rpm for 10  min. The supernatants were extracted 
with an equal volume of ethyl acetate twice, concen-
trated by rotary evaporator, and re-dissolved in 1.5  mL 
methanol. To extract the intracellular metabolites, cell 
pellets were resuspended in 10  mL 80  % acetone, soni-
cated, centrifuged and the supernatant was evaporated 
to remove the acetone. The procedure was repeated 
once. Subsequently, the remaining water phase was also 
extracted with an equal volume of ethyl acetate twice 
and re-dissolved in 1.5 mL methanol as the supernatant 
of the fermented broth. Then 20  µL extraction samples 
of the fermentation broth or the cell pellets were ana-
lyzed by HPLC–MS separately.
Compounds purification
2 L fermentation broth of the recombinant strain APG-1 
was centrifuged to separate into supernatant and cell 
pellets. After crude extraction using the above protocol, 
purification of HIBP and PIVP was conducted by semi-
preparative HPLC performed on a Shimadzu LC-6 AD 
with SPD-20A detector. The HPLC conditions were as 
follows: solvent A  =  H2O; solvent B  =  methanol; flow 
rate: 4 mL/min, 0–5 min 90 % A and 10 % B, 6–40 min 
90  % A and 10–100  % B (linear gradient), 41–45  min 
100  % B. A YMC-pack ODS-A (10 ×  250  mm; particle 
size, 5 μm) was used as the stationary phase.
Chemical analysis and quantification
HPLC–MS was performed on an Agilent 1260 system 
with 1260 Infinity UV detector and a Bruker microQ-
TOF II mass spectrometer equipped with an ESI ioni-
zation probe. The innoval C18 column (4.6 ×  250  mm; 
5 μm particle size) was used in this study. The HPLC con-
ditions for isovaleryl-CoA, HIBP and PIVP were as fol-
lows: solvent A =  H2O (containing 20  mM ammonium 
acetate for the analysis of isovaleryl-CoA, or containing 
0.1  % formic acid for the analysis of HIBP and PIVP); 
solvent B =  methanol; flow rate =  1  mL/min; 0–5  min 
95 % A and 5 % B, 6–45 min 95 % A and 5 % B to 100 % 
B (linear gradient). All these products were detected at 
254  nm. Standard calibration curve of isovaleryl-CoA 
was generated with a series of known concentrations 
of the isovaleryl-CoA standard purchased from Sigma-
Aldrich (Milwaukee, WI, USA). Standard calibration 
curves of HIBP and PIVP were generated with a series of 
known concentrations of the purified compounds from 
large scale fermentation. All experiments were carried 
Table 1 Bacterial strains and plasmids
CGMCC China general microbiological culture collection center
Name Description Reference
Plasmids
 pETDuet-1 pBR322 ori with PT7; Amp
R Novagen
 pCDFDuet-1 CDF ori with PT7; Sm
R Novagen
 pET-A pETDuet-1 carrying aibA, aibB, aibC and liuC This study
 pCDF-E pCDFDuet-1 carrying ERG10 and ERG13 This study
 pCDF-EV1 pCDFDuet-1 carrying ERG10, ERG13 and 
HlVPSsyn
This study
 pCDF-EV2 pCDFDuet-1 carrying ERG10, ERG13 and 
FvCHS2-1syn
This study






Myxococcus xanthus (CGMCC 1.3865) CGMCC
 Yeast Saccharomyces cerevisiae BY4742 29
 APG-0 E. coli BL21 (DE3) with pETDuet-1 and 
pCDFDuet-1
This study
 APG-IV E. coli BL21 (DE3) with pET-A and pCDF-E This study
 APG-1 E. coli BL21 (DE3) with pET-A and pCDF-EV1 This study
 APG-2 E. coli BL21 (DE3) with pET-A and pCDF-EV2 This study
 APG-3 E. coli BL21 (DE3) with pET-A and pCDF-EV3 This study
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out in triplicate and repeated at least twice. The titer was 
presented as mean ± SD.
NMR analysis
NMR experiments were performed on a Bruker Avance 
400 (Karlsruhe, Germany). The sample were dried by 
evaporation and dissolved in 500 µL of DMSO-d6 and 
transferred into 2.5 mm NMR tube. Chemical shifts were 
expressed in δ (ppm) and coupling constants (J) were 
given in Hertz (Hz) (Additional file 1: Figure S2).
HIBP 1H-NMR (DMSO-d6, 400  MHz) δ 5.94 (d, 
J  =  2.1  Hz, 1H), 5.21 (d, J  =  2.1  Hz, 1H), 2.30 (d, 
J = 7.2 Hz, 2H), 1.93 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H);
PIVP 1H-NMR (DMSO-d6, 400  MHz), δ 5.79 (s, 2H), 
2.86 (d, J = 6.8 Hz, 2H), 2.13 (m, 1H), 0.91 (d, J = 6.7 Hz, 
6H).
Results
Engineered synthesis of isovaleryl‑CoA in E. coli
First, we generated isovaleryl-CoA in E. coli cells 
employing a pathway from M. xanthus via hydroxy-
3-methylglutaryl CoA (HMG-CoA), a key intermediate 
of mevalonate pathway in the biosynthesis of isopre-
noids [24]. Short branched-chain acyl-CoAs are usu-
ally derived from the branched-chain amino acids as 
a mixture via transamination and subsequent oxida-
tive decarboxylation catalyzed by the branched-chain 
α-keto acid dehydrogenase complex (BCDH) [26]. In 
current work, acetyl-CoA is converted into HMG-CoA 
as in the mevalonate pathway (Fig. 2a). Enzymes ERG10 
(acetyl-CoA acetyltransferase) and ERG13 (HMG-CoA 
synthase) from S. cerevisiae were used for efficient bio-
synthesis of HMG-CoA, as these two enzymes yielded 
enhanced levels of mevalonate in E. coli [27–29]. The 
three enzymes from M. xanthus, including LiuC (HMG-
CoA dehydratase), AibA/B (3-methylglutaconyl-CoA 
(MG-CoA) decarboxylase) and AibC (3,3-dimethylacry-
lyl CoA (DMA-CoA) reductase), were used to transform 
HMG-CoA into isovaleryl-CoA consecutively via MG-
CoA and DMA-CoA in the above E. coli strain (Fig. 2a). 
Acyl-CoAs were extracted from the engineered E. coli 
strain APG-IV harboring pET-A and pCDF-E and ana-
lyzed by HPLC–MS with strain APG-0 harboring pET-
Duet-1 and pCDFDuet-1 as the negative control (Fig. 3). 
This procedure confirmed the production of isovaleryl-
CoA by comparing the retention time (tR  =  24.5  min) 
and the molecular ion [(M  +  H)+  =  852.1802] with 
those of the isovaleryl-CoA standard (Fig.  3b, c). The 
titer of isovaleryl-CoA from this new pathway was 
1421.8 ± 129.2 nmol/g wet weight, about sixteen times 
higher than the titer of our previous engineered E. coli 
strain using the BCDH complex under the same fermen-
tation and detection conditions (Fig. 3d) [26].
Engineered synthesis of PIVP and HIBP in E. coli carrying 
HlVPSsyn and optimization of fermentation conditions
The HlVPSsyn from hops was synthesized and intro-
duced into the isovaleryl-CoA producing E. coli strain, 
generating the recombinant strain APG-1. After fer-
mentation, the broth supernatants and cell pellets were 
analyzed by HPLC–MS. As shown in the chromato-
gram, the recombinant strain APG-1 produced two 
new compounds (Fig. 4c, d), compared with the control 
strain APG-0 (Fig.  4a, b). The first compound with a tR 
of 35.6  min was initially identified as HIBP by LC–MS 
(Additional file 1: Figure S2a, c; [M + H]+ = 169.0763). 
In the previous enzymatic studies, the production of 
HIBP was confirmed only by LC–MS analysis probably 
due to no enough products for NMR analysis [3, 23]. In 
this work, about 74.9  mg HIBP was isolated from 2  L 
scale culture, and we were able to confirm the structure 
by 1D-NMR spectroscopy analysis (Additional file  1: 
Figure S2a, c). The second product with a tR of 39.7 min 
was identified as PIVP (Additional file  1: Figure S2b, 
[M + H]+ = 211.0925). About 6.5 mg HIBP was isolated 
from 2 L culture, and the PIVP structure was further con-
firmed by 1H-NMR spectroscopy analysis (Additional 
file  1: Figure S2d). The localization of the two products 
was also tested. PIVP mainly accumulated in the cell pel-
lets (Fig. 4c), while HIBP was distributed in the fermenta-
tion broth as well as the cell pellets (Fig. 4c, d).
We further optimized the production of PIVP and 
HIBP by varying fermentation conditions for the recom-
binant strain APG-1 such as temperature and IPTG 
concentration at the first stage. The recombinant strain 
APG-1 was incubated in TB medium for 16 h at varying 
temperature (16, 23 or 30 °C) with a fixed IPTG concen-
tration of 0.1  mM. The cell pellets were harvested and 
resuspended in modified M9 medium and incubated at 
30  °C for 36 h. Combining both the fermentation broth 
and cell pellets, the titerss of PIVP and HIBP exhibited 
best at 23  °C (Fig.  5a). After that, different concentra-
tions of IPTG, 0.01, 0.05, 0.1, 0.2 and 0.4 mM were used 
to induce protein expression at 23 °C. The titers of PIVP 
and HIBP were highest when the concentration of IPTG 
was 0.05 mM as shown in Fig. 5b. Furthermore, we moni-
tored titers of PIVP and HIBP produced by APG-1 culti-
vated in modified M9 medium at different fermentation 
time. The results are summarized in Fig. 5c. The titers of 
HIBP and PIVP reached the highest in 24 h, which were 
52.0 ± 7.9 and 6.4 ± 0.6 mg/L, respectively. Under these 
concentrations, no inhibition on cell growth by the com-
pounds HIBP and PIVP was observed.
Biosynthesis of HIBP and PIVP in E. coli using CHSs
In addition to HlVPS, a CHS from strawberry (F. vesca), 
FvCHS2-1 played a role as a bifunctional CHS/VPS 
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enzyme [3]. We performed codon optimization for 
the FvCHS2-1 gene, synthesized and introduced the 
FvCHS2-1syn into the isovaleryl-CoA producing E. coli 
strain, generating APG-2 and fermented under the opti-
mized conditions. The protein expression was induced at 
23 °C for 16 h with 0.05 mM IPTG, and then the fermen-
tation was conducted in modified M9 medium at 30  °C 
for 24  h. HPLC analysis showed that the strain APG-2 
also produced HIBP and PIVP, although the titer of 
PIVP was much lower than that carrying HlVPSsyn, only 
1.4 ± 0.2 mg/L (Fig. 4e, f, j). However, the titer of HIBP 
reached 53.3 ± 9.0 mg/L, which was similar to that of the 
strain harboring HlVPSsyn (Fig. 4i).
VPS was involved in the formation of PIVP in the bio-
synthesis of humulone and could also produce PIPB 
using isobutyryl-CoA as the starter unit [21–23]. PIBP 
is the core structure of hyperforin, an antidepressant 
extracted from Hypericum species. The enzyme catalyz-
ing formation of PIBP is still unknown. It was assumed 
that there may be a VPS-like or dual functional CHS/VPS 
enzyme in the Hypericum species responsible for the for-
mation of PIBP, and more than likely, this enzyme could 
also use isovaleryl-CoA as the starter molecular to form 
PIVP and HIBP. Based on the reported type III PKSs gene 
sequences of the Hypericum species [30] in the NCBI 
database, several candidate genes were amplified from 
the callus of H. perforatum by homology cloning. Among 
these genes, a suspected CHS gene showing 96.2 % simi-
larity with FvCHS2-1 at the amino acid level was desig-
nated as HpCHS (GenBank: KU180217), and introduced 
into the above isovaleryl-CoA producer. The recombi-
nant E. coli strain APG-3 harboring the isovaleryl-CoA 
Fig. 3 Engineered synthesis of isovaleryl-CoA by E. coli strains. a HPLC analysis of chemical profiles produced by E. coli strain APG-0 harboring 
empty vectors. b HPLC analysis of isovaleryl-CoA produced by E. coli strain APG-IV carrying pET-A and pCDF-E. c The isovaleryl-CoA standard. d MS 
chromatogram showing the synthesis of isovaleryl-CoA. e Titers of isovaleryl-CoA produced by the recombinant strain APG-IV and our previous E. 
coli expressing the BCDH complex [26]
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pathway genes and HpCHS was fermented as described 
above. The HIBP titer produced by this strain reached 
66.5 ±  13.1 mg/L, which was the highest among all the 
three producers (Fig. 4g–i). The PIVP titer in APG-3 was 
2.8 ± 0.5 mg/L, which was lower than that of the APG-1 
harboring HlVPSsyn (Fig. 4g, h, j).
Discussion
Short branched-chain acyl-CoAs are important build-
ing blocks for a large number of valuable compounds 
[5, 24, 31]. However, native E. coli metabolism does not 
produce these short branched-chain acyl-CoAs, which 
hampers the heterologous production of those eco-
nomically important chemicals in this host. Previously 
engineered short branched-chain acyl-CoA producing 
E. coli strains usually biosynthesized isobutyryl-CoA, 
isovaleryl-CoA and 2-methyl-butyryl-CoA as a mixture 
derived from the metabolic pathways of branched-chain 
amino acids catalyzed by the BCDH complex [26, 32, 33]. 
In this study, we successfully demonstrated the feasibility 
of synthesizing isovaleryl-CoA in E. coli via HMG-CoA 
(Fig.  2a) recruiting five enzymes from yeast and myxo-
bacteria [24]. Isovaleryl-CoA was the only product in 
this pathway which makes the engineered E. coli strain 
more suitable for producing compounds such as humu-
lone and lupulone with isovaleryl-CoA as the building 
block. In the BCDH dependent pathway, isovaleryl-CoA 
and isobutyryl-CoA are derived from α-ketoisocaproate 
or α-ketoisovalerate directly, and α-ketoisovalerate is 
an intermediate for the formation of α-ketoisocaproate. 
Thus the formation of isobutyryl-CoA competes with 
isovaleryl-CoA in the pathway (Fig. 2a). Meanwhile short 
branched-chain keto acids would also be transformed 
into corresponding amino acids such as leucine, isoleu-
cine and valine beyond acyl-CoAs (Fig.  2a). HMG-CoA 
formation with ERG10 and ERG13 derived from acetyl-
CoA has been well established in the mevalonate pathway 
(Fig.  2a) in E. coli [27–29]. By recruiting LiuC, AibA/B 
and AibC, the HMG-CoA was further uniquely diverted 
into the formation of isovaleryl-CoA via MG-CoA and 
DMA-CoA. This engineered strain represents a novel 
“factory” for biosynthesis of a series of valuable chemicals 
with isovaleryl-CoA as the building block, including fatty 
acids, biofuels and natural products [26, 32, 33].
Introduction of VPS from hops, CHSs from strawberry 
or H. perforatum to the above isovaleryl-CoA produc-
ing E. coli strain resulted in the biosynthesis of PIVP 
and HIBP. PIVP was detected in hop extracts [34], and is 
the key intermediate of humulone, which contribute the 
characteristic bitter flavor of beer and display multiple 
pharmacological effects [4, 31]. The work described here 
may pave the way for synthesis of humulone and other 
derivatives. HIBP has not been isolated from any natural 
resources [11–13]. As an analogue of TAL, HIBP could 
be used as a potential platform chemical to produce vari-
ous chemical intermediates and end products with short 
Fig. 5 Optimization of fermentation conditions. a The titers of PIVP and HIBP by strain APG-1 at different protein induction temperature. b The titers 
of PIVP and HIBP by strain APG-1 at different IPTG concentration. c The titers of PIVP and HIBP by strain APG-1 at different fermentation time
(See figure on previous page.) 
Fig. 4 Engineered synthesis of 4-hydroxy-6-isovaleryl-2-pyrone (HIBP) and phlorisovalerophenone (PIVP) by E. coli strains. a, b Strain APG-0 harbor-
ing empty vectors as negative control. c, d Strain APG-1 harboring plasmids pET-A and pCDF-EV1. e, f Strain APG-2 harboring plasmids pET-A and 
pCDF-EV2. g, h Strain APG-3 harboring plasmids pET-A and pCDF-EV3. a, c, e, g HPLC analysis of metabolites extracted from cell pellets.  
b, d, f, h HPLC analysis of metabolites extracted from the fermentation broth. i The titers of HIBP produced by the strains APG-1, APG-2 and APG-3.  
j The titers of PIVP produced by the strains APG-1, APG-2 and APG-3
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branched-chains (Additional file 1: Figure S1a, b) [11–13, 
35]. More experiments are needed to test whether HIBP 
itself has any antibacterial or fungicidal activity or not.
In this study, the VPS from hops was the best enzyme 
for PIVP formation. The newly cloned CHS from H. per-
foratum was the most appropriate enzyme for the synthe-
sis of HIBP. The ratios of HIBP and PIVP were calculated 
based on the titers produced by strains APG-1 (52.0 over 
6.4 mg/L), APG-2 (53.3 over 1.4 mg/L) and APG-3 (66.5 
over 2.8  mg/L), which were about 8:1, 37:1 and 24:1, 
respectively. In the in  vitro enzyme activity analysis of 
HlVPS and FvCHS, PIVP was the major product, instead 
of HIBP [3, 22]. It was reported that the PIVP and HIBP 
content was affected by the relative ratio of isovaleryl-
CoA/malonyl-CoA in the in vitro experiment [3]. In our 
recombinant E. coli, the production of isovaleryl-CoA 
and malonyl-CoA both derived from acetyl-CoA, and 
there may be a dynamic balance between the concentra-
tion of isovaleryl-CoA and malonyl-CoA in vivo (Fig. 2a), 
which may affect the ratio of HIBP and PIVP.
Amino acids sequence alignment of HlVPS, FvCHS2-1 
and HpCHS showed high similarity (Additional file  1: 
Figure S4). The three essential catalytic amino acids Cys-
His-Asn, the active site loop of CHS enzymes GFGPG, 
and two Phe residues, important in determining the sub-
strate specificity of CHS are all well conserved in these 
three proteins (Additional file  1: Figure S4). However, 
ratios between PIVP and HIBP produced by these three 
enzymes are quite different (Fig. 4). Several protein engi-
neering studies have elucidated the basis of starter mol-
ecule selectivity and the control of polyketide length of 
type III PKSs. For example, Jez and colleagues reported 
that a triple mutant (T197L/G256L/S338I) of CHS, gen-
erated an enzyme that was functionally identical to 2-PS, 
catalyzing the synthesis of the TAL from an acetyl-CoA 
starter molecule and two malonyl-CoAs [36]. In 2005, 
Abe and co-workers reported that a point mutation 
(M207G) in a pentaketide chromone synthase (PCS) 
expanded the volume of the catalytic cavity, to con-
vert PCS into octaketide synthase [37]. Thus, modeling 
analyses and site-directed mutagenesis experiments are 
needed to improve the product specificity and increase 
the synthesis of PIVP or HIBP.
Directed evolution may be also used to increase the 
activity of HlVPS, FvCHS2-1 or HpCHS. Using directed 
evolution, Rao and colleagues obtained a series of ther-
mostable PhlD mutants with improved phloroglucinol 
productivity [19]. Recently, Tang and colleagues engi-
neered the E. coli regulatory protein AraC to activate 
gene expression in response to TAL, developed an endog-
enous TAL reporter system in E. coli. Using this system, 
they conducted in  vivo directed evolution of 2-PS in E. 
coli, and obtained a 2-PS variant conferring  ~20-fold 
higher TAL production [6]. Similar reporter systems may 
also be constructed in our recombinant E. coli to facili-
tate high throughput screening of HlVPS, FvCHS2-1 or 
HpCHS for improved productivity of HIBP or PIVP. At 
the same time, precursor supply including isovaleryl-CoA 
and malonyl-CoA may be improved for the production of 
HIBP and PIVP. The availability of intracellular malonyl-
CoA may be enhanced by over-expressing the acetyl-CoA 
carboxylase (Acc) and acetyl-CoA synthase (Acs) genes 
and deletion of competing pathways, which was applied 
in improving phloroglucinol productivity by engineered 
E. coli strain [19, 38]. In the case of HIBP and PIVP, as 
both substrates isovaleryl-CoA and malonyl-CoA were 
derived from acetyl-CoA, there may be a dynamic bal-
ance between these two substrates and may need more 
elaborate regulation.
Conclusions
In this work, we firstly constructed a biosynthetic path-
way of isovaleryl-CoA in E. coli by recruiting a route via 
hydroxy-3-methylglutaryl CoA, and then investigated the 
potential of bio-renewable production of PIVP and HIBP 
with E. coli as the host using type III PKSs. Even though 
still in infancy, the work described here may pave the way 
for microbial synthesis of not only acylphloroglucinols 
derivatives, but also “unnatural” TAL analogues.
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